Skip to main content
Top

23-02-2018 | Insulin | Practical approach | Article

Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes

Journal: Diabetes Therapy

Authors: Lori Berard, Noreen Antonishyn, Kathryn Arcudi, Sarah Blunden, Alice Cheng, Ronald Goldenberg, Stewart Harris, Shelley Jones, Upender Mehan, James Morrell, Robert Roscoe, Rick Siemens, Michael Vallis, Jean-François Yale

Publisher: Springer Healthcare

Abstract

It is currently estimated that 11 million Canadians are living with diabetes or prediabetes. Although hyperglycemia is associated with serious complications, it is well established that improved glycemic control reduces the risk of microvascular complications and can also reduce cardiovascular (CV) complications over the long term. The UKPDS and ADVANCE landmark trials have resulted in diabetes guidelines recommending an A1C target of ≤ 7.0% for most patients or a target of ≤ 6.5% to further reduce the risk of nephropathy and retinopathy in those with type 2 diabetes (T2D), if it can be achieved safely. However, half of the people with T2D in Canada are not achieving these glycemic targets, despite advances in diabetes pharmacological management. There are many contributing factors to account for this poor outcome; however, one of the major factors is the delay in treatment advancement, particularly a resistance to insulin initiation and intensification. To simplify the process of initiating and titrating insulin in T2D patients, a group of Canadian experts reviewed the evidence and best clinical practices with the goal of providing guidance and practical recommendations to the diabetes healthcare community at large. This expert panel included general practitioners (GPs), nurses, nurse practitioners, endocrinologists, dieticians, pharmacists, and a psychologist. This article summarizes the panel recommendations.
Literature
1.
DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(Suppl 2):S127–38.PubMedPubMedCentralCrossRef
2.
Pratley RE. The early treatment of type 2 diabetes. Am J Med. 2013;126(9 Suppl 1):S2–9.PubMedCrossRef
3.
Ross SA. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med. 2013;126(9 Suppl 1):S38–48.PubMedCrossRef
4.
Barag SH. Insulin therapy for management of type 2 diabetes mellitus: strategies for initiation and long-term patient adherence. J Am Osteopath Assoc. 2011;111(7 Suppl 5):S13–9.PubMed
5.
Lebovitz HE. Diabetes Review 1999;7(3):139–53.
6.
Palumbo PJ. The case for insulin treatment early in type 2 diabetes. Cleve Clin J Med. 2004;71(5):385–6.PubMedCrossRef
7.
Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18):1736–47.PubMedCrossRef
8.
Cheng AYY. The rules of 3s: insulin use in type 2 diabetes. Can Diabetes. 2011;24(1):3–9.
9.
Lovshin JA, Zinman B. Diabetes: clinical inertia–a barrier to effective management of T2DM. Nat Rev Endocrinol. 2013;9(11):635–6. https://​doi.​org/​10.​1038/​nrendo.​2013.​185.PubMed
10.
Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825–34.PubMedCrossRef
11.
Khunti K. Clinical inertia in the management of type 2 diabetes mellitus: a focused literature review. Br J Diabetes. 2015;15(2):65–9.CrossRef
12.
Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411–7. https://​doi.​org/​10.​2337/​dc13-0331.PubMedPubMedCentral
13.
Harris SB, Kapor J, Lank CN, Willan AR, Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Phys. 2010;56(12):e418–24.
14.
Khunti K, Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Prim Care Diabetes. 2017;11(1):3–12.PubMedCrossRef
15.
Cheng AY, et al. Barriers to achieve A1C target in patients with T2D: Key learnings from a Canadian personal practice assessment. December 2015; IDF/WDC Meeting 0738-P.
16.
Ng CJ, Lai PS, Lee YK, Azmi SA, Teo CH. Barriers and facilitators to starting insulin in patients with type 2 diabetes: a systematic review. Int J Clin Pract. 2015;69(10):1050–70.PubMedCrossRef
17.
Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl. 2009;164:6–10.CrossRef
18.
Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28.PubMedCrossRef
19.
Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med. 2006;23(7):736–42.PubMedCrossRef
20.
Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17(9):859–67.PubMedPubMedCentralCrossRef
21.
Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755–62.PubMedCrossRef
22.
Yki-Jarvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37(12):3235–43.PubMedCrossRef
23.
Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17(4):386–94.PubMedPubMedCentralCrossRef
24.
Riddle MC, Bolli GB, Home PD, et al. Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetes. Diabetes Technol Ther. 2016;18(4):252–7.PubMedPubMedCentralCrossRef
25.
Matsuhisa M, Koyama M, Cheng X, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Obes Metab. 2016;18(4):375–83.PubMedPubMedCentralCrossRef
26.
Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464–71.PubMedPubMedCentralCrossRef
27.
Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36(9):2536–42.PubMedPubMedCentralCrossRef
28.
Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig. 2013;4(6):605–12.PubMedPubMedCentralCrossRef
29.
Standl E, Owen DR. New long-acting basal insulins: does benefit outweigh cost? Diabetes Care. 2016;39(Supplement 2):S172–9.PubMedCrossRef
30.
Terauchi Y, Koyama M, Cheng X, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab. 2016;18(4):366–74.PubMedPubMedCentralCrossRef
31.
Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 units/mL versus glargine 100 Units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38(12):2217–25.PubMedCrossRef
32.
Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–507.PubMedCrossRef
33.
Polinski JM, Smith BF, Curtis BH, et al. Barriers to insulin progression among patients with type 2 diabetes: a systematic review. Diabetes Educ. 2013;39(1):53–65.PubMedCrossRef
34.
Powers MA, Bardsley J, Cypress M, et al. Diabetes self-management education and support in type 2 diabetes. Diabetes Educ. 2017;43(1):40–53. https://​doi.​org/​10.​1177/​0145721716689694​.PubMed
35.
Al Hamarneh YN, Charrois T, Lewanczuk R, Tsuyuki RT. Pharmacist intervention for glycaemic control in the community (the RxING study). BMJ Open. 2013;3(9):e003154.PubMedPubMedCentralCrossRef
36.
Furler J, O’Neal D, Speight J, et al. Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. BMJ. 2017;356:j783.PubMedCrossRef
37.
Kovacs Burns K, Nicolucci A, Holt RI, et al. Diabetes attitudes, wishes and needs second study (DAWN2): cross-national benchmarking indicators for family members living with people with diabetes. Diabet Med. 2013;30(7):778–88.PubMedCrossRef
38.
Peyrot M, Burns KK, Davies M, et al. Diabetes attitudes wishes and needs 2 (DAWN2): a multinational, multi-stakeholder study of psychosocial issues in diabetes and person-centred diabetes care. Diabetes Res Clin Pract. 2013;99(2):174–84.PubMedCrossRef
39.
Funnell MM. Overcoming barriers to the initiation of insulin therapy. Clin Diabetes. 2007;25(1):36–8.CrossRef
40.
Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32(1 Suppl):9S–18S.PubMedCrossRef
41.
Skovlund SE, Peyrot M. The diabetes attitudes, wishes, and needs (DAWN) program: a new approach to improving outcomes of diabetes care. Diabetes Spect. 2005;18(3):136–42.CrossRef
42.
Polonsky WH, Jackson RA. What’s so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes. 2004;22(3):147–50.CrossRef
43.
Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543–5.PubMedCrossRef
44.
Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: a systematic review. Diabet Med. 2013;30(5):512–24.PubMedCrossRef
45.
Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33(4):733–5.PubMedPubMedCentralCrossRef
46.
Lebovitz HE. Type 2 diabetes: an overview. Clin Chem. 1999;45(8 Pt 2):1339–45.PubMed
47.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.CrossRef
48.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.PubMedCrossRef
49.
Kostev K, Dippel FW, Rathmann W. Risk of hypoglycaemia in type 2 diabetes patients under different insulin regimens: a primary care database analysis. Ger Med Sci. 2015;12(13):Doc01.
50.
Polonsky WH, Fisher L, Hessler D, Edelman SV. Identifying the worries and concerns about hypoglycemia in adults with type 2 diabetes. J Diabetes Complic. 2015;29(8):1171–6.CrossRef
51.
Vallis M, Jones A, Pouwer F. Managing hypoglycemia in diabetes may be more fear management than glucose management: a practical guide for diabetes care providers. Curr Diabetes Rev. 2014;10(6):364–70.PubMedCrossRef
52.
Clayton D, Woo V, Yale J-F. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: hypoglycemia. Can J Diabetes 2013;37(suppl 1):S69–71.
53.
Harper W, Clement M, Goldenberg R, et al. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: pharmacologic management of type 2 diabetes. Can J Diabetes 2013;37(suppl 1):S61–68.
54.
Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384–95.PubMedPubMedCentralCrossRef
55.
Sorli C, Heile MK. Identifying and meeting the challenges of insulin therapy in type 2 diabetes. J Multidiscip Healthc. 2014;7:267–82.PubMedPubMedCentralCrossRef
56.
Polonsky WH, Arsenault J, Fisher L, et al. Initiating insulin: how to help people with type 2 diabetes start and continue insulin successfully. Int J Clin Pract. 2017. https://​doi.​org/​10.​1111/​ijcp.​12973.PubMedPubMedCentral
57.
Arnolds S, Heise T, Flacke F, Sieber J. Common standards of basal insulin titration in type 2 diabetes. J Diabetes Sci Technol. 2013;7(3):771–88.PubMedPubMedCentralCrossRef
58.
Sabourin BC, Pursley S. Psychosocial issues in diabetes self-management: strategies for healthcare providers. Can J Diabetes. 2013;37(1):36–40.PubMedCrossRef
59.
Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28(6):1282–8.PubMedCrossRef
60.
Blonde L, Merilainen M, Karwe V, Raskin P. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE study. Diabetes Obes Metab. 2009;11(6):623–31.PubMedCrossRef
61.
Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes–results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007;9(6):902–13.PubMedCrossRef
62.
Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J. Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use). Adv Ther. 2013;30(6):607–22.PubMedPubMedCentralCrossRef
63.
Berard L, Harris SB, Yale J-F, Groleau M, Javadi P, Stewart J. Safety and efficacy of a pragmatic self-titration 1 unit/day (INSIGHT) algorithm for insulin glargine 300 U/mL (Gla-300). Can J Diabetes. 2016;40(5):S47.CrossRef
64.
Yale JF, Berard L, Groleau M, Javadi P, Stewart J, Harris SB. TITRATION: a randomized study to assess 2 treatment algorithms with new insulin glargine 300 units/ml. Can J Diabetes. 2017;41(5):478–84. https://​doi.​org/​10.​1016/​j.​jcjd.​2017.​06.​007.PubMed
65.
Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29(5):682–9.PubMedPubMedCentralCrossRef
66.
Berard L, Bonnemaire M, Mical M, Edelman S. Insights into optimal basal insulin titration in type 2 diabetes: results of a quantitative survey. Diabetes Obes Metab. 2018;20(2):301–8.PubMedPubMedCentralCrossRef
67.
Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: what progress have we made? Diabetes Metab Res Rev. 2014;30(2):104–19.PubMedCrossRef
68.
TOUJEO™SoloSTAR® Product Monograph May 28, 2015.
70.
Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723–32.PubMedPubMedCentralCrossRef
71.
Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944–50.PubMedCrossRef
72.
Lajara R, Cengiz E, Tanenberg RJ. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes. Curr Med Res Opin. 2017;33(6):1045–55.PubMedCrossRef
73.
Bramlage P, Bluhmki T, Fleischmann H, et al. Determinants of weight change in patients on basal insulin treatment: an analysis of the DIVE registry. BMJ. 2017;5(1):e000301.
74.
Garber AJ. Will the next generation of basal insulins offer clinical advantages? Diabetes Obes Metab. 2014;16(6):483–91.PubMedCrossRef
75.
Owens DR. Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. Diabetes Technol Ther. 2013;15:776–85.
76.
Steinstraesser A, Schmidt R, Bergmann K, Dahmen R, Becker RH. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab. 2014;16(9):873–6.PubMedPubMedCentralCrossRef
77.
Goldman J, Kapitza C, Pettus J, Heise T. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. Curr Med Res Opin. 2017;33(10):1821–31.PubMedCrossRef
78.
de Galan BE. Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives. Patient Prefer Adher. 2016;10:2097–106.CrossRef
79.
Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 units. mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units. mL-1. Diabetes Care. 2015;38(4):637–43. https://​doi.​org/​10.​2337/​dc14-0006.PubMed
80.
Marso SP, McGuire DK, Zinman B, et al. Design of DEVOTE (trial comparing cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes at high risk of cardiovascular events) - DEVOTE 1. Am Heart J. 2016;179:175–83. https://​doi.​org/​10.​1016/​j.​ahj.​2016.​06.​004.PubMed
81.
Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005;28(3):600–6.PubMedCrossRef
82.
Blonde L, Merilainen M, Karwe V, Raskin P, Group TS. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATETM study. Diabetes Obes Metab. 2009;11(6):623–31.PubMedCrossRef
83.
Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–6.PubMedCrossRef
84.
Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49(3):442–51.PubMedCrossRef
85.
Harris S, Yale JF, Dempsey E, Gerstein H. Can family physicians help patients initiate basal insulin therapy successfully? Randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. Can Fam Physician. 2008;54(4):550–8.PubMedPubMedCentral
86.
Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36(4):858–64.PubMedPubMedCentralCrossRef
87.
Partners HealthCare. Partners guidelines for the treatment of type 2 diabetes in the non-pregnant adult. Partners Healthcare; 2012. http://​vdc.​partners.​org/​guidelines/​Guidelines_​7-10-12.​pdf.
88.
Staples H, Yale JF. Starting Insulin. Booklet based on INSIGHT Study conducted 2002–2004. Aventis Pharma.
89.
Glasgow Diabetes Managed Clinical Network. Guidelines for insulin initiation and adjustment in primary care in patients with type 2 diabetes: for the guidance of diabetes specialist nurses. Greater Glasgow and Clyde: NHS; 2010.
90.
Heise T, Meneghini LF. Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr Pract. 2014;20(1):75–83.PubMedCrossRef
91.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2013;37:S1–212.CrossRef
92.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Appendix 3: Examples of insulin initiation and titration regimens in people with type 2 diabetes. Can J Diabetes 2013;37:S200–S1.
93.
Bergenstal RM, Johnson M, Powers MA, et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care. 2008;31(7):1305–10.PubMedPubMedCentralCrossRef
94.
Buse JB, Wolffenbuttel BH, Herman WH, et al. The DURAbility of basal versus lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. Diabetes Care. 2011;34(2):249–55.PubMedPubMedCentralCrossRef
95.
Kennedy L, Herman WH, Strange P, Harris A. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with algorithms and labs at Point of Care (GOAL A1C) trial. Diabetes Care. 2006;29(1):1–8.PubMedCrossRef
96.
Charbonnel B, DeFronzo R, Davidson J, et al. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab. 2010;95(5):2163–71.PubMedCrossRef
97.
Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010;33(7):1509–15.PubMedPubMedCentralCrossRef
99.
Leiter LA, Berard L, Bowering CK, et al. Type 2 diabetes mellitus management in Canada: is it improving? Can J Diabetes. 2013;37(2):82–9.PubMedCrossRef

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »